Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
13,594 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.
Rajaram R, Huang Q, Li RZ, et al. · Chest · 2024Systematic Review, Meta-Analysis
- Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M, Fan Y, Nie L, et al. · Chest · 2022Meta-Analysis, Systematic Review
- Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.
Ginsberg RJ, Rubinstein LV · Ann Thorac Surg · 1995Clinical Trial, Comparative Study
- Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis.
Liu N, Zhang B, He J, et al. · Front Immunol · 2025Network Meta-Analysis, Systematic Review
- Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.
Chen K, Wang X, Yue R, et al. · Front Immunol · 2024Systematic Review, Network Meta-Analysis
- What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis.
Zhang W, Zhang X, Zhao W, et al. · BMC Pulm Med · 2024Systematic Review, Network Meta-Analysis
- Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W, Liang Z, Zhao Y, et al. · Front Immunol · 2024Meta-Analysis, Systematic Review
- Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Han C, Qiu J, Bai L, et al. · Int J Radiat Oncol Biol Phys · 2024Systematic Review, Meta-Analysis
- Effectiveness of Baduanjin exercise on pulmonary function, quality of life, psychological well-being and exercise tolerance in postoperative patients with non-small cell lung cancer: Systematic review and meta-analysis of randomized controlled trials.
Yan Z, Chen M, Tao J, et al. · Explore (NY) · 2025Systematic Review, Meta-Analysis
- Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K, Shimokawa M, Mizuki F, et al. · Eur J Med Res · 2022Meta-Analysis, Systematic Review
- Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer.
Franek J, Cappelleri JC, Larkin-Kaiser KA, et al. · Future Oncol · 2019Systematic Review, Network Meta-Analysis
- Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Wu S, Wang L, Li W, et al. · Ann Palliat Med · 2021Meta-Analysis, Systematic Review
- Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Waser NA, Quintana M, Schweikert B, et al. · JNCI Cancer Spectr · 2024Systematic Review, Meta-Analysis
- Sarcopenia and survival in surgically treated non-small cell lung cancer: A systematic review and meta-analysis.
Lading T, Media AS, Tellefsen B, et al. · Eur J Surg Oncol · 2025Systematic Review, Meta-Analysis
- Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.
Yan Q, Li S, He L, et al. · Front Immunol · 2024Systematic Review, Meta-Analysis
- Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis.
Wang Y, Wan Y, Qian Y · Comput Math Methods Med · 2021Meta-Analysis, Systematic Review
- Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F, Zhang W, Shang X, et al. · Crit Rev Oncol Hematol · 2022Systematic Review, Network Meta-Analysis
- Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K, Yamamoto S, Nagata C, et al. · Lung Cancer · 2017Meta-Analysis, Systematic Review
- Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.
Li XY, Lin JZ, Yu SH · Clin Ther · 2020Systematic Review, Network Meta-Analysis
- A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W, Zhang T, Zhang Q, et al. · BMC Pulm Med · 2022Meta-Analysis, Systematic Review
- Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer.
Blom EF, Haaf KT, de Koning HJ · Pharmacoeconomics · 2020Meta-Analysis, Research Support, N.I.H., Extramural
- Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
Viani GA, Gouveia AG, Louie AV, et al. · Radiother Oncol · 2024Systematic Review, Meta-Analysis
- Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Wang Y, Wang M, Wang Q, et al. · Oncotarget · 2017Meta-Analysis, Systematic Review
- Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).
Lenderking WR, Lin H, Speck RM, et al. · Future Oncol · 2019Clinical Trial, Phase II, Randomized Controlled Trial
- Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis.
Zhou C, Li M, Wang Z, et al. · Int Immunopharmacol · 2022Systematic Review, Network Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.